MedTrace Logo

Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

NCT02147015 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2020-10-26

No results posted yet for this study

Summary

The hypothesis is that in acute exacerbated Chronic Obstructive Pulmonary Disease (AECOPD), personalized variable dose glucocorticoid treatment will result in superior clinical outcome when compared to fixed dose therapy.

Conditions

Interventions

DRUG

Glucocorticoids

DRUG

Antibiotics

DRUG

Inhaled corticosteroid (ICS)

DRUG

Long-Acting Muscarinic Antagonists(LAMA)

DRUG

Short-acting beta2-agonist (SABA)

OTHER

Physical treatments

DRUG

long-acting beta2-agonist (LABA)

Sponsors & Collaborators

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Principal Investigators

  • Guoqiang Cao, Medical Doctor · Daping Hospital, Third Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2017-12-31
Completion
2018-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02147015 on ClinicalTrials.gov